TAMPA, Fla., April 27 /PRNewswire-FirstCall/ -- Calvin A. Grant, MD, Retina Macular Care, presented the results from his 60-patient retrospective case control study that was designed to evaluate the adjuvant use of Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R) (ranibizumab) treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) in an oral poster presentation at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Dr. Grant reported patients who received Xibrom in addition to Lucentis (the Combination Group) required 1.6 +/- 0.69 injections of Lucentis during the six-month study period, while patients who received Lucentis only received 4.5 +/- 0.41 injections (p=0.0002). The original abstract, which was published in February 2008, stated there was a numerical trend in favor of the Combination Group on improvement in visual acuity but this difference did not achieve statistical significance. However, upon rigorous review and further statistical analysis, the data has shown the Combination Group did show a statistically significant improvement in visual acuity. In the Combination Group, mean visual acuity increased 1.2 +/- 1.64 lines compared with 0.06 +/-0.66 lines in patients in the Lucentis-only group (p=0.001).
The study results were gathered from 60 patients receiving Lucentis therapy for wet AMD. Patients were monitored monthly using optical coherence tomography (OCT) and fluorescein angiography. When subretinal fluid from leaking vessels was detected by OCT, patients were re-injected with Lucentis. 30 patients received Xibrom dosed twice daily in addition to the Lucentis injection (the Combination Group), and their results were compared to 30 patients who received Lucentis only. There were no adverse events associated with the extended topical administration of bromfenac.
|SOURCE ISTA Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved